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ABSTRACT
A patient with high grade undifferentiated pleomorphic soft-tissue sarcoma 
from a striated muscle was grown orthotopically in the right biceps femoris muscle 
of mice to establish a patient-derived orthotopic xenograft (PDOX) model. Twenty 
PDOX mice were divided into 4 groups: G1, control without treatment; G2, Salmonella 
typhimurium (S. typhimurium) A1-R administered by intratumoral (i.t.) injection once 
a week for 4 weeks; G3, doxorubicin (DOX) administered by intraperitoneal (i.p.) 
injection once a week for 4 weeks; G4, S. typhimurium A1-R (i.t.) administered once 
a week for 2 weeks followed by i.p. doxorubicin once a week for 2 weeks. On day 25 
from the initiation of treatment, tumor volume in G2, G3, and G4 was significantly 
lower than G1. Mice found without gross tumor included one mouse (20%) in G2; one 
mouse (20%) in G3; and 3 mice (60%) in G4. Body weight loss did not significantly 
differ between the 3 treated groups or from the untreated control. Histological 
examination revealed eradication of tumor only in G4 where mice were treated with 
S. typhimurium A1-R followed by DOX. Our present study indicates future clinical 
potential of combining S. typhimurium A1-R with chemotherapy such as DOX for soft 
tissue sarcoma patients.
INTRODUCTION
For soft-tissue sarcoma, the 5-year survival for 
patients with metastatic disease is less than 20% [1, 2]. 
Doxorubicin (DOX) treatment for advanced soft tissue 
sarcoma resulted in a median survival of only 18 months. 
Therefore, development of improved treatment is needed. 
Records for almost 300 years have documented 
cancer patients going into remission after a bacterial 
infection if they survived the infection [3]. For example, in 
1867, Busch reported that a malignant tumor disappeared 
when the patient contracted what is now known as 
Streptococcus pyogenes [4]. 
In the late nineteenth century, William B. Coley 
at Memorial Hospital in New York, the precursor of 
Memorial Sloan-Kettering Cancer Center, treated cancer 
patients with S. pyogenes. Coley’s first patient infected 
with S. pyogenes recovered from head and neck cancer. 
Coley injected many cancer patients with S. pyogenes and 
often had good results [3].
Salmonella typhimurium (S. typhimurium), is a 
facultative anaerobe which confers important advantages 
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as a potential cancer therapeutic, in that a facultative 
anaerobe can grow in the oxic viable region of tumors as 
well as necrotic regions [5]. In a Phase I clinical trial on 
patients with metastatic melanoma and renal carcinoma, 
the S. typhimurium strain tested (VNP20009), attenuated 
by msbB and purI mutations, was safely administered to 
patients [6].
The tumor-targeting S. typhimurium A1-R strain 
developed by our laboratory has higher tumor-colonization 
efficacy and antitumor efficacy than S. typhimurium-
VNP20009 [7], possibly because it has fewer attenuation 
mutations. S. typhimurium A1-R is auxotrophic for 
Leu—Arg, which prevents it from mounting a continuous 
infection in normal tissues. S. typhimurium A1-R was able 
to inhibit or eradicate primary and metastatic tumors as 
monotherapy in nude mouse models of prostate [8, 9], 
breast [10-12], lung [13, 14], pancreatic [15-19], ovarian 
[20, 21] stomach [22], and cervical cancer [23], as well 
as sarcoma cell lines [24-26] and glioma [27, 28], all of 
which are highly aggressive tumor models.
Previously, we developed a patient-derived 
orthotopic xenograft (PDOX) nude-mouse model of soft-
tissue sarcoma. The sarcoma was resistant to gemcitabine. 
Pazopanib tended to reduce the tumor volume compared to 
the untreated mice, but there was no significant difference. 
However, S. typhimurium A1-R significantly inhibited 
tumor growth compared to the untreated mice. These 
results suggest tumor-targeting S. typhimurium A1-R 
is a promising treatment for chemo-resistant soft-tissue 
sarcoma [29].
A human patient with advanced leiomyosarcoma 
was treated with an intratumoral injection of Clostridium 
novyi (C. novyi-NT) spores which reduced the tumor 
within and surrounding the bone [30]. 
Since S. typhimurium A1-R is a facultative anaerobe, 
unlike C. novyi-NT, which is an obligate anaerobe, it 
was thought to have more broad application for cancer 
therapy. In addition, since S. typhimurium A1-R can 
greatly potentiate cytotoxic chemotherapy and the fact that 
DOX is first-line therapy for soft tissue sarcoma, it was 
appropriate to determine the efficacy of S. typhimurium 
A1-R followed by DOX in a PDOX model of soft tissue 
sarcoma compared to either therapy alone. 
RESULTS AND DISCUSSION
Effects of single agent and combined S. 
typhimurium A1-R and DOX on sarcoma PDOX 
growth
On the 25th day from initiation of treatment, tumor 
volume was significantly smaller in the animals treated 
with S. typhimurium A1-R (G2) (245.3 ± 141.6 mm3, 
p < 0.01); the animals treated with DOX (G3) (165.5 ± 
247.7 mm3, p < 0.05); and the animals treated with S. 
typhimurium A1-R followed by DOX (G4) (138.4 ± 209.3 
mm3, p < 0.01) compared to the untreated control animals 
(G1) (1460.3 ± 1136.6 mm3, Figure 2). There were no 
significant differences in tumor volume between G2, G3, 
and G4. One tumor in G2, 1 tumor in G3, and 3 tumors in 
G4 achieved complete remission (no detectable tumor). 
Mouse body weight did not significantly differ between 
the 3 treatment groups, and the treatment groups did not 
significantly differ in body weight from the untreated 
control group. Since the tumor diameter in G1 reached 
20 mm after the 25th treatment day, all mice in G1 were 
sacrificed by the 29th day.
Histological response to chemotherapy
Tumors were mainly comprised of viable spindle 
shaped cells in the tumors from the untreated animals (G1) 
(Figure. 3A, 3B). In G2 treated with S. typhimurium A1-R 
forty to 60% of the tumor tissue consisted of viable tissue 
(Grade IIA or IIB), whereas the other part was replaced 
by necrosis or inflammatory cells (Figure 3C, 3D). The 
response of tumors treated with DOX alone (G3) varied 
widely; one tumor showed no necrosis (Grade I; Figure 
3E), two tumors had a small amount of necrosis (Grade 
IIA), and the other tumor was necrotic without viable 
cells (Grade IV; Figure 3F). The two tumors which did 
not undergo complete remission in G4 were comprised of 
large areas of necrosis or inflammation (Grade III; Figure 
3G, 3H). Tumors in G4, treated with the combination of 
S. typhimurium A1-R followed by DOX were considered 
Table 1: Treatment response between groups
G1:  Untreated control
G2:  S. typhimurium A1-R-alone
G3:  Doxorubicin-alone
G4:  S. typhimurium A1-R followed by doxorubicin
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Figure 1: Treatment model and protocol. A. Soft tissue sarcoma PDOX mouse model. Ten days after surgical orthotopic implantation 
(SOI), tumors in the right biceps femoris muscle had grown more than 5 mm in diameter. Arrow indicates a grown tumor. Scale bar: 10 mm. 
B. Treatment protocol. G1: untreated control; G2: treated with S. typhimurium A1-R (A1-R)-alone (i.t., 5 × 107 CFU/body, weekly, 4 weeks) 
G3: treated with doxorubicin (DOX)-alone (i.p., 3 mg/kg, weekly, 4 weeks); G4: treated with S. typhimurium A1-R (i.t., 5 × 107 CFU/body, 
weekly, 2 weeks) followed by DOX (i.p., 3 mg/kg, weekly, 2 weeks). Each group contained 5 mice.
Figure 2: S. typhimurium and A1-R doxorubicin or their combination significantly inhibited tumor growth in a soft tissue sarcoma 
PDOX model. Graph shows tumor volume at each time point. On day 25 from initial treatment, tumor volume in G2 (S. typhimurium A1-
R-alone) (245.3 ± 141.6 mm3, p < 0.01); G3 (DOX-alone) (165.5 ± 247.7 mm3, p < 0.05); and G4 (S. typhimurium A1-R followed by DOX) 
(138.4 ± 209.3 mm3, p < 0.01) was significantly smaller than in G1. There was not a significant difference between the treated groups. Error 
bars: + 1 SD. 
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eradicated. These results were summarized in Table 1.
Recently we established a soft tissue sarcoma 
PDOX model in which the mouse-grown tumors more 
closely recapitulated the human histology, as compared to 
xenografts [31] implanted subcutaneously. This may be a 
general phenomenon for all tumor types [32]. 
The higher rate eradication of tumors by the 
combination of S. typhimurium and DOX may be 
attributable to the “decoy” effect of S. typhimurium A1-R 
[33], which induces quiescent cells to cycle, there by 
making them more susceptible to chemotheraphy than 
when the cancer cells are in G1/G0 which are the majority 
of cells in a solid tumor [34]. Future experiments will 
investigate this possibility. 
Figure 3: Histological response. Untreated tumors (G1) were comprised of spindle-shaped viable sarcomatous cells without necrosis 
or inflammatory change A. B. Tumors treated with S. typhimurium A1-R (G2) had components of inflammation (C. Grade IIB), or necrosis 
(D. Grade IIA). One of the tumors treated with doxorubicin (DOX) (G3) showed no necrosis (E. Grade I), while another tumor showed 
complete tumor necrosis (F. Grade IV). Tumors treated with the combination of S. typhimurium A1-R and DOX were destroyed and 
replaced with inflammatory-type cells (G. H. Grade III). Hematoxylin and eosin staining. Scale bars: 100 μm.
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Recently, Roberts et al. [30] treated a patient with 
advanced leiomyosarcoma with spores of the obligate 
anaerobe C. novyi-NT. A single metastasis was injected 
with the C. novyi-NT spore and appeared to be completely 
destroyed. The patient died due to other lesions of the 
leiomyosarcoma. The fact that C. novyi-NT is an obligate 
anaerobe may preclude its systemic administration and 
may limit its treatment to i.t. injection. This should not 
be the case for the facultative anaerobe S. typhimurium 
A1-R, where we have shown in previous experiments 
to be effective against tumors when administered i.v. 
Although, i.t. administration of S. typhimurium A1-R was 
used in the present experiment as a model for clinical 
testing, future treatment of soft tissue sarcoma will utilize 
i.v. administration as well. Future experiments will test 
simultaneous treatment of S. typhimurium A1-R and DOX 
to determine synergy.
CONCLUSIONS
The combination of S. typhimurium A1-R and 
subsequent DOX eradicated a soft tissue sarcoma in a 
PDOX mouse model. In the early part of the 20th century, 
bacterial therapy of sarcoma was first-line therapy under 
William B. Coley at the Memorial Hospital of New York. 
Since DOX is presently considered first-line therapy of 
soft tissue sarcoma, the combination of DOX with S. 
typhimurium A1-R has important future clinical potential, 
which we hope can be realized in the near future. Another 
potential future clinical strategy is to combine sarcoma 
surgery with adjuvant S. typhimurium A1-R which we 
have shown to be highly effective in mouse models [35].
MATERIALS AND METHODS
Mice
Athymic nu/nu nude mice (AntiCancer Inc., San 
Diego, CA), 4-6 weeks old, were used in this study. 
All animal studies were conducted with an AntiCancer 
Institutional Animal Care and Use Committee (IACUC)-
protocol specifically approved for this study and in 
accordance with the principals and procedures outlined in 
the National Institute of Health Guide for the Care and 
Use of Animals under Assurance Number A3873-1. In 
order to minimize any suffering of the animals, the use 
of anesthesia and analgesics were used for all surgical 
experiments. Animals were anesthetized by subcutaneous 
injection of a 0.02 ml solution of 20 mg/kg ketamine, 15.2 
mg/kg xylazine, and 0.48 mg/kg acepromazine maleate. 
The response of animals during surgery was monitored 
to ensure adequate depth of anesthesia. The animals 
were observed on a daily basis and humanely sacrificed 
by CO2 inhalation when they met the following humane 
endpoint criteria: severe tumor burden (more than 20 
mm in diameter), prostration, significant body weight 
loss, difficulty breathing, rotational motion and body 
temperature drop. Animals were housed in a barrier facility 
on a high efficiency particulate arrestance (HEPA)-filtered 
rack under standard conditions of 12-hour light/dark 
cycles. The animals were fed an autoclaved laboratory 
rodent diet. 
Patient-derived tumor
A large right thigh high-grade undifferentiated 
pleomorphic sarcoma was resected by F.C.E., Division of 
Surgical Oncology, University of California, Los Angeles 
(UCLA). The patient did not receive any chemotherapy 
or radiotherapy prior to surgery. Written informed 
consent was obtained from the patient as part of a UCLA 
Institutional Review Board (IRB #10-001857) approved 
protocol.
Establishment of a PDOX model of soft tissue 
sarcoma by surgical orthotopic implantation 
(SOI)
A fresh sample of a soft tissue sarcoma which had 
grown in striated muscle of a patient was obtained and 
transported immediately to the laboratory at AntiCancer, 
Inc., on wet ice. The sample was cut into 5-mm fragments 
and implanted subcutaneously in nude mice. After three 
weeks, the subcutaneously-implanted tumors grew to 
more than 10 mm in diameter. The subcutaneously-
grown tumors were then harvested and cut into small 
fragments (3 mm3). After the mice were anesthetized 
with the ketamine solution described above, a 5-mm skin 
incision was made on the right high thigh into the biceps 
femoris, which was split to make space for the sarcoma 
tissue fragment. A single tumor fragment was implanted 
orthotopically into the space to establish the PDOX model. 
The wound was closed with a 6-0 nylon suture (Ethilon, 
Ethicon, Inc., NJ, USA). 
Preparation and administration of S. typhimurium 
A1-R
GFP-expressing S. typhimurium A1-R bacteria 
(AntiCancer, Inc., San Diego, CA, USA) were grown 
overnight on LB medium and then diluted 1:10 in LB 
medium. Bacteria were harvested at late-log phase, 
washed with PBS, and then diluted in PBS. S. typhimurium 
A1-R was injected intratumorally. A total of 5 × 107 CFU 
S. typhimurium A1-R in 50 μl PBS was administered to 
each tumor. 
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Treatment study design in the PDOX model of 
soft tissue sarcoma
Ten days after orthotopic implantation, tumors 
reached 5 mm in diameter (Figure 1A). Twenty PDOX 
model mice were randomized into 4 groups of 5 mice each 
(Figure 1B): G1, control without treatment; G2, treated 
with S. typhimurium A1-R; i.t. once a week for 4 weeks; 
G3, treated with 3 mg/kg doxorubicin (pfizer, NewYork, 
NY,) i.p. once a week for 4 weeks, G4: treated with S. 
typhimurium A1-R (i.t.) once a week for 2 weeks followed 
by doxorubicin i.p. once a week for 2 weeks. Tumor 
length, width and mouse body weight were measured 
twice in a week. Tumor volume was calculated with the 
following formula: Tumor volume (mm3) = length (mm) 
× width (mm) × width (mm) × 1/2. Data are presented as 
mean ± SD. When a tumor was not detectible, the tumor 
response was considered as complete remission. All 
treated mice were sacrificed on day 29, and tumors were 
resected for further histological evaluation. 
Histological examination
Fresh tumor samples were fixed in 10% formalin 
and embedded in paraffin before sectioning and staining. 
Tissue sections (5 μm) were deparaffinized in xylene and 
rehydrated in an ethanol series. Hematoxylin and eosin 
(H &E) staining was performed according to standard 
protocol. Histological examination was performed with 
a BHS System Microscope (Olympus Corporation, 
Tokyo, Japan). Images were acquired with INFINITY 
ANALYZE software (Lumenera Corporation, Ottawa, 
Canada). Histological response was evaluated according 
to the Evans grading system that had been developed 
for human-cancer histological-response evaluation after 
chemo-radiotherapy [36]. Briefly, histological response 
was classified as follows; Grade I: no or little ( < 10%) 
cancer-cell destruction; Grade IIA: 10-49% cancer-cell 
destruction; Grade IIB: 50-89% cancer cell destruction; 
Grade III: few ( < 10%) viable cancer cells are present, 
Grade IV: no viable tumor is detectible. 
Statistical analysis
SPSS statistics version 21.0 was used for all 
statistical analyses (IBM, New York City, NY, USA). 
Significant differences for continuous variables were 
determined using the Mann-Whitney U test. A probability 
value of P < 0.05 was considered statistically significant. 
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